Zalicus Inc. (ZLCS) Reports Financial Results For The Fourth Quarter And Year-End 2013
3/13/2014 6:53:23 AM
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ended December 31, 2013.
“With the successful translation of Z944 in a human clinical pain model, Zalicus has initiated a Phase 1 clinical study to evaluate the pharmacokinetics and safety of multiple modified-release formulations of Z944,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus.
Help employers find you! Check out all the jobs and post your
comments powered by